Impact of drug price revisions and lower income from overseas licensees
First written in FY2017-Q1. 23 of 34 entries say "Materialised", first in FY2017-Q3. Latest entry: FY2026.
Kaken Pharmaceutical moved to the "Worse" side of this theme in 2017.
0 other companies' latest entry also says "Materialised".
- FY2026MaterialisedAnnual report
「In the domestic pharmaceuticals business, the national healthcare budget remains under pressure as society ages, while various measures to contain medical costs, including sweeping reform of the drug pricing system, are being implemented. The business environment therefore remains challenging during the consolidated fiscal year, including as a result of the introduction of a selective medical care system for long-listed products.」
Amid continued drug pricing system reform, measures to contain medical costs, and the selective medical care system for long-listed products, lower sales of Alz and other products due to drug price revisions and other factors, as well as lower pharmaceutical revenue, were reflected in the full-year results. - 2026-05-13MaterialisedRevisions to earnings forecasts
「売上高および各利益項目が減少した主な要因は、前期において、2024 年 5 月 29 日に公表しました「NM26 の知的財産譲渡及び販売提携オプション契約の締結」に基づく契約一時金（総額 8,600 万米ドル）ならびに、2024 年 12 月 26 日に公表しました「STAT6 阻害剤に関するライセンス契約締結のお知らせ」に基づく契約一時金（3,000 万米ドル）を受領したことの反動によるものです。」
前期に受領した2件のライセンス関連契約一時金の反動による収入減少が、2026年3月期の個別業績減少として記載された。 - FY2026-H1MaterialisedAnnual report
「Various measures to contain medical costs, including sweeping reform of the drug pricing system, are being implemented, and the business environment remains challenging during the interim consolidated accounting period, including as a result of the selective medical care system for long-listed products. Although sales of Ecloc, a treatment for primary axillary hyperhidrosis, and other products increased, sales of Alz, a joint function improvement agent, and generic drugs, excluding Krenafin AG, declined due to the impact of the drug price revision and other factors, resulting in lower revenue.」
Drug pricing system reform, measures to contain medical costs, and the selective medical care system for long-listed products continue to be cited as challenging business conditions, while the impact of the drug price revision is reflected in the results as lower sales of Alz and other products and lower pharmaceutical revenue. - FY2025-H1WorsenedAnnual report
「Various measures to contain medical costs, including sweeping reform of the drug pricing system, are being implemented, and the business environment remains challenging during the interim consolidated accounting period, including as a result of the planned introduction of a selective medical care system for long-listed products.」
In addition to drug pricing system reform and measures to contain medical costs, the decision to introduce a selective medical care system for long-listed products has been indicated, giving concrete form to the challenging environment surrounding the domestic pharmaceuticals business. - FY2024-Q3MaterialisedAnnual report
「In the domestic pharmaceuticals business, the national healthcare budget remains under pressure as society ages, while various measures to contain medical costs, including sweeping reform of the drug pricing system, are being implemented. The business environment therefore remains challenging during the cumulative third-quarter period, including due to the implementation of an interim-year drug price revision.」
The challenging business environment resulting from measures to contain medical costs, including drug pricing system reform and interim-year drug price revisions, continues and is reflected in the results as a factor behind the decline in pharmaceutical sales. - FY2024-Q2MaterialisedAnnual report
「In the domestic pharmaceuticals business, the national healthcare budget remains under pressure as society ages, while various measures to contain medical costs, including sweeping reform of the drug pricing system, are being implemented. The business environment therefore remains challenging during the cumulative second-quarter period, including due to the implementation of an interim-year drug price revision.」
The challenging business environment resulting from measures to contain medical costs, including drug pricing system reform and interim-year drug price revisions, continues, and is reported in the results together with a decline in product sales. - FY2024-Q1RestatedAnnual report
「In the domestic pharmaceuticals business, the national healthcare budget remains under pressure as society ages, while various measures to contain medical costs, including sweeping reform of the drug pricing system, are being implemented. The business environment therefore remains challenging during the cumulative first-quarter period, including due to the implementation of an interim-year drug price revision.」
The challenging business environment resulting from measures to contain medical costs, including drug pricing system reform and interim-year drug price revisions, continues to be reported. - FY2023-Q3MaterialisedAnnual report
「Revenue was ¥55,573 million, down 3.7% year on year, with the impact of the drug price revision cited as the primary cause of the decline.」
The impact of the drug price revision materialized as an actual decline in revenue, with revenue for the cumulative third-quarter consolidated period down 3.7% year on year. - FY2023-Q2MaterialisedAnnual report
「Revenue was ¥36,819 million, down 2.0% year on year, with the impact of the drug price revision cited as the primary cause of the decline.」
The impact of the drug price revision materialized as an actual decline in revenue, with revenue for the cumulative second-quarter consolidated period down 2.0% year on year. - FY2023-Q1MaterialisedAnnual report
「Net sales were ¥18,197 million, down 1.4% year on year, with the impact of drug price revisions cited as the main factor behind the decline in revenue.」
The impact of the drug price revision materialized as the primary cause of the decline in revenue in the first quarter, with revenue down 1.4% year on year. This is a quantified result, so materialized was set to true. - FY2022RestatedAnnual report
「In the domestic pharmaceuticals business, various measures to contain medical costs, including policies to promote the use of generic drugs and fundamental reforms to the drug pricing system, are being implemented as national healthcare finances come under pressure due to rapid population aging and other factors,」
Government policy developments, including reforms to the drug pricing system and measures to promote the use of generic drugs, continue to be identified as major risks that could affect business performance. - FY2022-Q3RestatedAnnual report
「Net sales were ¥57,708 million, up 1.1% year on year. Despite the impact of drug price revisions, revenue increased due to contributions from new products and a rebound from patients refraining from visiting medical institutions as COVID-19 infections spread.」
The impact of drug price revisions continued to be cited, but cumulative third-quarter net sales increased 1.1% year on year due to contributions from new products and a rebound from patients refraining from seeking medical care. - FY2022-Q2RestatedAnnual report
「Net sales were ¥37,588 million, up 2.2% year on year. Despite the impact of drug price revisions, revenue increased due to contributions from new products and a rebound from patients refraining from visiting medical institutions as COVID-19 infections spread.」
The impact of drug price revisions continued to appear in the business performance commentary, but revenue increased during the cumulative second quarter due in part to a rebound from patients refraining from seeking medical care. The report states that there were no significant changes in the risk associated with drug price revisions. - FY2022-Q1RestatedAnnual report
「Net sales were ¥18,453 million, up 2.1% year on year. Despite the impact of drug price revisions, revenue increased due in part to a rebound from patients refraining from visiting medical institutions as COVID-19 infections spread.」
The impact of drug price revisions continued to be cited, but quarterly net sales increased 2.1% year on year, partly due to a rebound from patients refraining from seeking medical care. - FY2021MaterialisedAnnual report
「In pharmaceuticals and medical devices, revenue declined due to lower sales of ARTZ, a joint function improvement agent, and KLEENAFIN, a treatment for onychomycosis, as well as lower overseas sales.」
The impact of drug price revisions was compounded by patients refraining from seeking medical care due to COVID-19 and lower overseas sales, resulting in consolidated net sales of ¥74,979 million, down 16.0% year on year. - FY2021-Q3RestatedAnnual report
「The Group reported lower revenue and lower profit for the cumulative third quarter of the consolidated fiscal year. Net sales were ¥57,082 million, down 18.7% year on year. The main factors behind the decline included the impact of drug price revisions and patients refraining from visiting medical institutions as COVID-19 infections spread.」
The impact of drug price revisions continued to be cited as the main factor behind the decline in revenue. Patients refraining from seeking medical care due to COVID-19 were also cited as a factor, but are being tracked in a separate thread. - FY2021-Q2MaterialisedAnnual report
「The Group reported lower revenue and lower profit for the cumulative second quarter of the consolidated fiscal year. Net sales were ¥36,789 million, down 18.6% year on year. The main factors behind the decline included the impact of drug price revisions and patients refraining from visiting medical institutions as COVID-19 infections spread.」
The impact of drug price revisions, together with patients refraining from seeking medical care due to COVID-19, emerged as an actual decline in consolidated net sales of 18.6% year on year. - FY2021-Q1MaterialisedAnnual report
「The Group reported lower revenue and lower profit for the cumulative first quarter of the consolidated fiscal year. Net sales were ¥18,070 million, down 19.1% year on year. The main factors behind the decline included the significant impact of drug price revisions and the impact of patients refraining from visiting medical institutions as COVID-19 infections spread.」
In addition to the impact of drug price revisions, patients refraining from visiting medical institutions due to the spread of COVID-19 emerged as an actual factor behind the decline in revenue. - FY2020-Q3MaterialisedAnnual report
「The factors included the impact of competing products, including generic drugs, and drug price revisions.」
The impact of competing products, including generic drugs, and drug price revisions continued to be reflected in results, with pharmaceutical sales down 3.4% year on year and consolidated net sales down 3.3% year on year. - FY2020-Q2MaterialisedAnnual report
「The Group’s net sales for the cumulative second quarter of the consolidated fiscal year were ¥45,170 million, down 4.9% year on year, mainly due to lower overseas sales and other factors.」
Lower overseas sales and other factors emerged as actual drivers of the decline in consolidated net sales during the cumulative second quarter of the consolidated fiscal year, with net sales down 4.9% year on year. - FY2020-Q1MaterialisedAnnual report
「The Group’s net sales for the cumulative first quarter of the consolidated fiscal year were ¥22,335 million, down 7.5% year on year, mainly due to lower overseas sales and other factors.」
Lower overseas sales emerged as an actual factor behind the decline in consolidated net sales in the first quarter, with net sales down 7.5% year on year. - FY2019MaterialisedAnnual report
「The Group’s net sales for the consolidated fiscal year were ¥94,165 million, down 4.3% year on year, mainly due to the impact of drug price revisions.」
The impact of drug price revisions emerged as an actual factor behind the annual decline in revenue. The impact of measures to promote the use of generic drugs for long-listed products also continued, and consolidated net sales fell 4.3% year on year. - FY2019-Q3MaterialisedAnnual report
「The Group’s net sales for the cumulative third quarter of the consolidated fiscal year were ¥72,584 million, down 5.6% year on year, mainly due to the impact of drug price revisions. This was primarily attributable to the significant impact of drug price revisions and the continuing impact of the government’s measures to promote the use of generic drugs.」
The impact of drug price revisions and measures to promote the use of generic drugs continued to emerge as actual factors behind the decline in revenue during the cumulative third quarter of the consolidated fiscal year. - FY2019-Q2MaterialisedAnnual report
「The Group’s net sales for the cumulative second quarter of the consolidated fiscal year were ¥47,521 million, down 4.7% year on year, mainly due to the impact of drug price revisions. This was primarily attributable to the significant impact of drug price revisions and the continuing impact of the government’s measures to promote the use of generic drugs.」
The impact of drug price revisions and measures to promote the use of generic drugs continued to emerge as actual factors behind the decline in revenue during the cumulative second quarter of the consolidated fiscal year. - FY2019-Q1MaterialisedAnnual report
「In pharmaceuticals and medical devices, sales of KLEENAFIN, a treatment for onychomycosis, increased, but revenue declined due to lower sales of ARTZ, a joint function improvement agent, and SEPRAFILM, an absorbable adhesion barrier, among other factors. The main factor behind the decline in revenue was the significant impact of drug price revisions, while the impact of the government’s measures to promote the use of generic drugs also continued. Although sales of KLEENAFIN increased, the increase was not sufficient to offset the decline in the other products.」
The impact of drug price revisions and measures to promote the use of generic drugs emerged as actual factors behind the decline in pharmaceutical sales in the first quarter. Pharmaceutical sales were ¥23,551 million, down 3.4% year on year. - FY2018MaterialisedAnnual report
「In pharmaceuticals and medical devices, sales of KLEENAFIN, a treatment for onychomycosis, and ARTZ, a joint function improvement agent, were broadly in line with the previous year. However, revenue declined due to lower sales of SEPRAFILM, an absorbable adhesion barrier, and lower income from overseas licensees of KLEENAFIN, among other factors.」
Lower income from overseas licensees of KLEENAFIN, together with lower sales of SEPRAFILM, emerged as actual factors behind the annual decline in pharmaceutical sales. - FY2018-Q3RestatedAnnual report
「In pharmaceuticals and medical devices, sales of ARTZ, a joint function improvement agent, and KLEENAFIN, a treatment for onychomycosis, were broadly in line with the previous year. However, revenue declined due to lower sales of SEPRAFILM, an absorbable adhesion barrier, and lower income from overseas licensees of KLEENAFIN, among other factors.」
Lower income from overseas licensees of KLEENAFIN and lower sales of SEPRAFILM continued to be cited as factors behind the decline in pharmaceutical sales from the previous quarter. - FY2018-Q2MaterialisedAnnual report
「In pharmaceuticals and medical devices, sales of ARTZ, a joint function improvement agent, and KLEENAFIN, a treatment for onychomycosis, were broadly in line with the previous year. However, revenue declined due to lower sales of SEPRAFILM, an absorbable adhesion barrier, and lower income from overseas licensees of KLEENAFIN, among other factors.」
In addition to the existing factors behind the decline in revenue, lower sales of SEPRAFILM are explicitly identified as a factor behind the decline in pharmaceutical sales. - FY2018-Q2MaterialisedAnnual report
「Revenue declined due to lower income from overseas licensees of KLEENAFIN, among other factors.」
Lower income from overseas licensees of KLEENAFIN continued to be an actual factor behind the decline in pharmaceutical sales during the cumulative second quarter of the consolidated fiscal year. Pharmaceutical sales were ¥48,659 million, down 4.6% year on year. - FY2018-Q1MaterialisedAnnual report
「Revenue declined due to lower income from overseas licensees of KLEENAFIN, among other factors.」
Lower income from overseas licensees of KLEENAFIN continued to be an actual factor behind the decline in revenue in the first quarter. Net sales were ¥24,967 million, down 4.8% year on year. - FY2017ReframedAnnual report
「Various healthcare system reforms are progressing as measures to contain medical costs, and changes in the market environment may affect business performance.」
In addition to the historical decline in revenue caused by drug price revisions, changes in the market environment resulting from measures to contain medical costs and broader healthcare system reforms are identified as business risks. - FY2017-Q3MaterialisedAnnual report
「Revenue declined due to the impact of drug price revisions and lower income from overseas licensees of KLEENAFIN, among other factors.」
The impact of drug price revisions and lower income from overseas licensees of KLEENAFIN continued to be actual factors behind the decline in revenue during the cumulative third quarter of the consolidated fiscal year. Net sales were ¥78,965 million, down 7.6% year on year. - FY2017-Q2RestatedAnnual report
「Revenue declined due to the impact of drug price revisions and lower income from overseas licensees of KLEENAFIN, among other factors.」
The impact of drug price revisions and lower income from overseas licensees of KLEENAFIN continue to be cited as factors behind the decline in revenue. The quarterly report states that there were no significant changes in business or other risks. - FY2017-Q1First statedAnnual report
「Net sales were ¥26,228 million, down 5.1% year on year, mainly due to the impact of drug price revisions.」
The impact of drug price revisions and lower income from overseas licensees of KLEENAFIN were cited as factors behind the decline in revenue for the quarter.